Janssen Biotech, Inc.
97 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 6 name spellings.
80
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Methods of Inhibiting T-Cell Mediated B-Cell Antibody Production Using ANTI-CD27 Antibodies (US 10,301,392) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 7 fees due Dec 6 to 27, 2026 · next Dec 6
- 9 fees due Jan 7 to 25, 2027 · next Jan 7
- 8 fees due Feb 1 to 22, 2027 · next Feb 1
- 8 fees due Mar 5 to 24, 2027 · next Mar 5
- 7 fees due Apr 6 to 29, 2027 · next Apr 6
- 5 fees due May 10 to 28, 2027 · next May 10
- 14 fees due Jun 1 to 30, 2027 · next Jun 1
- 8 fees due Jul 9 to 30, 2027 · next Jul 9
- 7 fees due Aug 6 to 27, 2027 · next Aug 6
- 6 fees due Sep 10 to 30, 2027 · next Sep 10
- 8 fees due Oct 2 to 28, 2027 · next Oct 2
- 3 fees due Nov 14, 2027
Recent changes
- 7 of the patents on this record were granted since Aug 17, 2026
- 7 terms have ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,993,645 | Human ANTI-IL-23 Antibodies, Compositions, Methods and Uses In force · Medium confidence | In force | Medium confidence | |
| US 8,106,177 | Nucleic Acids Encoding Human ANTI-IL-23 Antibodies In force · High confidence | In force | High confidence | |
| US 8,221,760 | Methods of Treatment Using Human ANTI-IL-23 Antibodies In force · Low confidence | In force | Low confidence | |
| US 9,353,181 | Human Anti-IL-23 Antibodies, Compositions, Methods and Uses In force · Low confidence | In force | Low confidence | |
| US 9,783,607 | Human Anti-IL-23 Antibodies, Compositions, Methods and Uses In force · Medium confidence | In force | Medium confidence | |
| US 10,030,070 | Human Anti-IL-23 Antibodies, Compositions, Methods and Uses In force · Low confidence | In force | Low confidence | |
| US 10,954,297 | Methods of Treatment Using Human Anti-IL-23 Antibodies In force · Low confidence | In force | Low confidence | |
| US 12,129,293 | Medical Device for Administering Anti-IL-23 Antibodies In force · Low confidence | In force | Low confidence | |
| US 7,598,083 | Chemically Defined Media Compositions In force · High confidence | In force | High confidence | |
| US D677,382 | Drug Delivery Device In force · High confidence | In force | High confidence |
Also on record, not counted in the 415: 97 patents in force now held by others · 93 lapsed for an unpaid fee · 53 ended at full term · 5 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
198 pending · 231 abandoned · 7 no status recorded